Seth J Rotz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8567899/publications.pdf

Version: 2024-02-01

471509 501196 1,013 61 17 28 citations h-index g-index papers 62 62 62 1723 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Severe cytokine release syndrome in a patient receiving PDâ€1â€directed therapy. Pediatric Blood and Cancer, 2017, 64, e26642.	1.5	131
2	Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1671-1677.	2.0	58
3	ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy. New England Journal of Medicine, 2017, 376, 1189-1190.	27.0	50
4	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 662-673.	2.4	48
5	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Advances, 2021, 5, 1-11.	5.2	46
6	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668.	5.9	40
7	Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e65-e73.	2.0	40
8	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 2020, 4, 983-992.	5.2	34
9	Limitations of HLHâ€2004 criteria in distinguishing malignancyâ€associated hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2018, 65, e27400.	1.5	31
10	Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circulation Research, 2022, 130, 632-651.	4.5	29
11	A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1453-1461.	2.4	28
12	A View from the past into our collective future: the oncofertility consortium vision statement. Journal of Assisted Reproduction and Genetics, 2021, 38, 3-15.	2.5	25
13	Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant. Pediatric Blood and Cancer, 2017, 64, e26600.	1.5	24
14	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation, 2019, 25, e46-e54.	2.0	24
15	Use of complement monoclonal antibody eculizumab in Shiga toxin producing <i>Escherichia coli</i> associated hemolytic uremic syndrome: A review of current evidence. Pediatric Blood and Cancer, 2019, 66, e27913.	1.5	23
16	Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, e11-e19.	2.0	21
17	Sickle cell disease: A primary care update. Cleveland Clinic Journal of Medicine, 2020, 87, 19-27.	1.3	21
18	In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Advances, 2017, 1, 1632-1634.	5.2	20

#	Article	IF	CITATIONS
19	Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. Journal of Thrombosis and Thrombolysis, 2021, 51, 854-869.	2.1	20
20	Cerebral Vascular Abnormalities in Pediatric Patients With Sickle Cell Disease After Hematopoietic Cell Transplant. Journal of Pediatric Hematology/Oncology, 2014, 36, 190-193.	0.6	16
21	Non-Graft-versus-Host Disease Ocular Complications after Hematopoletic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow	2.0	16
22	Prevalence of sickle cell disease, hemoglobin S, and hemoglobin C among Haitian newborns. American Journal of Hematology, 2013, 88, 827-828.	4.1	15
23	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	6.2	14
24	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	2.4	14
25	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094.	5.2	14
26	Levocarnitine for pegaspargaseâ€induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Medicine, 2021, 10, 7551-7560.	2.8	14
27	Nocturnal hemoglobin desaturation is associated with reticulocytosis in adults with sickle cell disease and is independent of obstructive sleep apnea. American Journal of Hematology, 2016, 91, E355-6.	4.1	13
28	Pulmonary hypertension associated with bronchiolitis obliterans after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 310-312.	2.4	13
29	Teamâ€based approach to identify cardiac toxicity in critically ill hematopoietic stem cell transplant recipients. Pediatric Blood and Cancer, 2017, 64, e26513.	1.5	13
30	Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood and Cancer, 2018, 65, e27260.	1.5	13
31	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2020, 26, 1505-1510.	2.0	11
32	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	1.2	11
33	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
34	The microbiome in pediatric oncology. Cancer, 2020, 126, 3629-3637.	4.1	10
35	Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2021, 27, 679.e1-679.e8.	1.2	10
36	Assessment beyond central line bundle: Audits for line necessity in infected central lines in a surgical intensive care unit. American Journal of Infection Control, 2012, 40, 88-89.	2.3	9

#	Article	IF	CITATIONS
37	Challenges in the Treatment of Sarcomas of Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology, 2017, 6, 406-413.	1.3	9
38	Ethical conundrums in pediatric genomics. Hematology American Society of Hematology Education Program, 2018, 2018, 301-306.	2.5	9
39	Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia. Cancer, 2020, 126, 5319-5327.	4.1	8
40	The ASHâ€ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Pediatric Blood and Cancer, 2021, 68, e28967.	1.5	8
41	Continuous infusion chemotherapy, radiotherapy, and FDGâ€PET are feasible during extracorporeal membrane oxygenation. Pediatric Blood and Cancer, 2020, 67, e28429.	1.5	7
42	Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. Reproductive BioMedicine Online, 2022, 44, 81-92.	2.4	6
43	The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Blood Advances, 2022, 6, 679-685.	5.2	6
44	Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. Transplantation and Cellular Therapy, 2022, 28, 233-241.	1.2	5
45	Heterozygous <i>CTLA4</i> splice site mutation c.458-1G > C presenting with immunodeficiency and variable degree of immune dysregulation in three generation kindred of Caribbean descent. Pediatric Hematology and Oncology, 2021, 38, 658-662.	0.8	4
46	Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 217.e1-217.e6.	1.2	4
47	Safety of allogeneic hematopoietic stem cell transplantation in betaâ€thalassemia patients with chronic hepatitis C infections treated at a pediatric center. Pediatric Transplantation, 2019, 23, e13520.	1.0	3
48	Treatment exposures stratify need for echocardiographic screening in asymptomatic long-term survivors of hematopoietic stem cell transplantation. Cardiology in the Young, 2019, 29, 338-343.	0.8	3
49	Right-to-Left Shunts Are Unexpectedly Common in Adults with HbSS. Blood, 2016, 128, 3659-3659.	1.4	2
50	Type 2B von Willebrand Disease: An Unusual Cause of Severe Neonatal Thrombocytopenia. Journal of Pediatric Hematology/Oncology, 2017, 39, 473-475.	0.6	1
51	A Case of Congenital Anaplastic Large Cell Lymphoma in a Very Preterm Low–Birth Weight Neonate. Journal of Pediatric Hematology/Oncology, 2020, 42, e377-e380.	0.6	1
52	Brachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case report. Pediatric Hematology and Oncology, 2021, 38, 179-183.	0.8	1
53	Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series. Pediatric Hematology and Oncology, 2022, 39, 80-82.	0.8	1
54	Post-Transplantation Cyclophosphamide. JACC: CardioOncology, 2021, 3, 260-262.	4.0	1

SETH J ROTZ

#	Article	IF	Citations
55	Nocturnal Hypoxemia (not sleep apnea) May Drive Reticulocytosis in Sickle Cell Disease. Blood, 2014, 124, 1384-1384.	1.4	1
56	Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Cell Transplantation: A Case Report. Blood, 2021, 138, 4865-4865.	1.4	1
57	Abnormal Maximal and Submaximal Cardiopulmonary Exercise Capacity in Pediatric Stem Cell Transplant Recipients Despite Normal Standard Echocardiographic Parameters: A Pilot Study. Transplantation and Cellular Therapy, 2022, 28, 263.e1-263.e5.	1.2	1
58	Fecal microbiota of adolescent and young adult cancer survivors and metabolic syndrome: an exploratory study. Pediatric Hematology and Oncology, 2022, 39, 629-643.	0.8	1
59	Stop Light: Mortality Risk In Adult Sickle Cell Disease and Criteria For Hematopoietic Stem Cell Transplant. Blood, 2013, 122, 2227-2227.	1.4	O
60	Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 99-99.	1.4	0
61	Genome Wide Association Study of Pregnancy in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	0